title: Disease-modifying effect of intravenous immunoglobulin in an experimental model of epilepsy.
abstract: Novel therapies that prevent or modify the development of epilepsy following an initiating brain insult could significantly reduce the burden of this disease. In light of evidence that immune mechanisms play an important role in generating and maintaining the epileptic condition, we evaluated the effect of a well-established immunomodulatory treatment, intravenous immunoglobulin (IVIg), on the development of epilepsy in an experimental model of epileptogenesis. In separate experiments, IVIg was administered either before (pre-treatment) or after (post-treatment) the onset of pilocarpine status epilepticus (SE). Our results show that both pre- and post-treatment with IVIg attenuated acute inflammation in the SE model. Specifically, IVIg reduced local activation of glial cells, complement system activation, and blood-brain barrier damage (BBB), which are all thought to play important roles in the development of epilepsy. Importantly, post-treatment with IVIg was also found to reduce the frequency and duration of subsequent spontaneous recurrent seizures as detected by chronic video-electroencephalographic (video-EEG) recordings. This finding supports a novel application for IVIg, specifically its repurposing as a disease-modifying therapy in epilepsy.
authors.affiliation: Centre for Advanced Imaging, The University of Queensland, Brisbane, 4072, Australia.
authors.forename: Min
authors.initials: M
authors.lastname: Chen
authors.affiliation: School of Biomedical Sciences, The University of Queensland, Brisbane, 4072, Australia.|Department of Physiology, Yong Loo Lin School of Medicine, The National University of Singapore, 117597, Singapore.
authors.forename: Thiruma V
authors.initials: TV
authors.lastname: Arumugam
authors.affiliation: Centre for Advanced Imaging, The University of Queensland, Brisbane, 4072, Australia.
authors.forename: Gayeshika
authors.initials: G
authors.lastname: Leanage
authors.affiliation: Centre for Advanced Imaging, The University of Queensland, Brisbane, 4072, Australia.
authors.forename: Quang M
authors.initials: QM
authors.lastname: Tieng
authors.affiliation: Centre for Advanced Imaging, The University of Queensland, Brisbane, 4072, Australia.
authors.forename: Ashwin
authors.initials: A
authors.lastname: Yadav
authors.affiliation: Centre for Advanced Imaging, The University of Queensland, Brisbane, 4072, Australia.
authors.forename: Jeremy F P
authors.initials: JF
authors.lastname: Ullmann
authors.affiliation: Centre for Advanced Imaging, The University of Queensland, Brisbane, 4072, Australia.|Department of Physiology, Yong Loo Lin School of Medicine, The National University of Singapore, 117597, Singapore.
authors.forename: David T
authors.initials: DT
authors.lastname: She
authors.affiliation: Centre for Advanced Imaging, The University of Queensland, Brisbane, 4072, Australia.
authors.forename: Vy
authors.initials: V
authors.lastname: Truong
authors.affiliation: School of Biomedical Sciences, The University of Queensland, Brisbane, 4072, Australia.|Queensland Brain Institute, The University of Queensland, Brisbane, 4072, Australia.
authors.forename: Marc J
authors.initials: MJ
authors.lastname: Ruitenberg
authors.affiliation: Centre for Advanced Imaging, The University of Queensland, Brisbane, 4072, Australia.
authors.forename: David C
authors.initials: DC
authors.lastname: Reutens
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000473:pathology; D003176:Complement C3 / Q000378:metabolism; D004195:Disease Models, Animal; D004827:Epilepsy / Q000188:drug therapy*; D006624:Hippocampus / Q000473:pathology; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D051379:Mice; D017628:Microglia / Q000473:pathology; D009410:Nerve Degeneration / Q000473:pathology
chemical_list: D003176:Complement C3; D016756:Immunoglobulins, Intravenous